Investor Presentation First Nine Months of 2023

27 Investor presentation First nine months of 2023 The acquisition of Dicerna Pharmaceuticals and their RNAi technology in 2021 provided access to intracellular targets Disease targets (expressed genes) • Opportunity to silence genes Cell ~5,000 extracellular targets ~21,000 intracellular targets • Drugability of intracellular targets • RNA: Ribonucleic acid; mRNA: messenger RNA XX Genes (DNA) on chromosomes Peptides and proteins m RNAi Cm mRNA • Highly specific for targeted gene Reversible yet long-acting therapies Engage on the temporary genetic level with RNA therapeutics Novo NordiskⓇ

View entire presentation